News
Why Antares Pharma Inc Plummeted Today
Shares of Antares Pharma (NASDAQ: ATRS) are down 38% at 2:36 p.m. EDT after the company said -- in not so many words -- that it expects the Food and Drug Administration to reject the marketing....
ALPHA MOS : INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS
INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS PREVUES PAR L'ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L'ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AUTORITE DES MARCHES....
BASTIDE : Nombre d'actions et de droits de vote au 30 septemebre 2017
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12 avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
DROITS DE....
3 Growth Stocks at Value Stock Prices
It's not surprising that after an eight-year bull market, some are saying value investing is dead. With the cyclically adjusted P/E ratio of the S&P running at a red-hot 31, finding a value....
Exact Sciences Stock Just Hit an All-Time High: Here's Why It Could Go Even Higher
In May, Andrew Left of Citron Research blasted Exact Sciences (NASDAQ: EXAS), calling the stock "a poster child for what goes wrong when Wall Street gets a hold of a healthcare concept with no....
3 Healthcare Value Stocks
When value investors search through 10-Ks and valuation ratios for stocks selling on the cheap, healthcare isn't typically a sector full of stocks selling at a deep discount. When those stocks go....
3 Healthcare Value Stocks
When value investors search through 10-Ks and valuation ratios for stocks selling on the cheap, healthcare isn't typically a sector full of stocks selling at a deep discount. When those stocks go....
3 Healthcare Value Stocks
When value investors search through 10-Ks and valuation ratios for stocks selling on the cheap, healthcare isn't typically a sector full of stocks selling at a deep discount. When those stocks go....
Why 2017 Could Be This Stock's Best Year Yet
Nearly five years ago, Abbott Labs spun off its biopharmaceutical unit into a separate entity. That new company, AbbVie (NYSE: ABBV), enjoyed a tremendous first year, with its share price soaring....
Why 2017 Could Be This Stock's Best Year Yet
Nearly five years ago, Abbott Labs spun off its biopharmaceutical unit into a separate entity. That new company, AbbVie (NYSE: ABBV), enjoyed a tremendous first year, with its share price soaring....
Why 2017 Could Be This Stock's Best Year Yet
Nearly five years ago, Abbott Labs spun off its biopharmaceutical unit into a separate entity. That new company, AbbVie (NYSE: ABBV), enjoyed a tremendous first year, with its share price soaring....
Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap
If 2017 ended today, Aurinia Pharmaceuticals (NASDAQ: AUPH) would rank as one of the biggest winners of the year among biopharmaceutical stocks. Aurinia's share price has more than tripled so far....
2 Reasons Pfizer Is on Our Minds Today
In this Market Foolery podcast, and with the big news coming out of healthcare, host Chris Hill calls upon the expert insight of Industry Focus: Healthcare host Kristine Harjes.First, they....
2 Reasons Pfizer Is on Our Minds Today
In this Market Foolery podcast, and with the big news coming out of healthcare, host Chris Hill calls upon the expert insight of Industry Focus: Healthcare host Kristine Harjes.First, they....
Why Ardelyx Inc Skyrocketed Higher Today
Ardelyx (NASDAQ: ARDX) stock rose 44% on Thursday after the company announced positive data from the phase 3 T3MPO-2 trial testing its irritable bowel syndrome drug, tenapanor, after the close of....
Why AcelRx Pharmaceuticals Inc Got Cut in Half Today
AcelRx Pharmaceuticals (NASDAQ: ACRX) is down 57% at 12:41 p.m. EDT after the Food and Drug Administration rejected the company's pain medication Dsuvia. As I said earlier this month when the....
Carl Zeiss Meditec – Geht es jetzt auf neue Jahreshochs?
Die Aktie von Carl Zeiss Meditec ist im Jahr 2017 mit einem Kursplus von 30% bereits recht gut gelaufen. Das aktuelle Jahreshoch bei 47,78 Euro muss jedoch nicht das Ende der Fahnenstange....
Carl Zeiss Meditec – Geht es jetzt auf neue Jahreshochs?
Die Aktie von Carl Zeiss Meditec ist im Jahr 2017 mit einem Kursplus von 30% bereits recht gut gelaufen. Das aktuelle Jahreshoch bei 47,78 Euro muss jedoch nicht das Ende der Fahnenstange....
3 Signs Myriad Genetics' High-Growth Days Are Over
Myriad Genetics (NASDAQ: MYGN) used to be the creme de la creme of the genetic testing industry. It had healthy profit margins, a growing business, and was well-known among investors and health....
7 Essential Rules for Investing in Biotech Stocks
Successful investing boils down to minimizing risk while maximizing the potential for reward. That's true whether you're investing in stocks, bonds, cryptocurrencies, or anything else. But how you....
5 Game-Changing Cancer Drug Innovations Being Developed Right Now
Image source: Getty Images."The emperor of all maladies, the king of terrors." This phrase was used by a 19th century surgeon to describe cancer. More than a century later, the description....
5 Game-Changing Cancer Drug Innovations Being Developed Right Now
Image source: Getty Images."The emperor of all maladies, the king of terrors." This phrase was used by a 19th century surgeon to describe cancer. More than a century later, the description....
How Safe Is AbbVie's Dividend?
The pharmaceutical industry has been a favorite among dividend investors, and AbbVie (NYSE: ABBV) has put together an impressive track record of treating its shareholders well. Dating back to....
How Safe Is AbbVie's Dividend?
The pharmaceutical industry has been a favorite among dividend investors, and AbbVie (NYSE: ABBV) has put together an impressive track record of treating its shareholders well. Dating back to....
How Safe Is AbbVie's Dividend?
The pharmaceutical industry has been a favorite among dividend investors, and AbbVie (NYSE: ABBV) has put together an impressive track record of treating its shareholders well. Dating back to....